Marone C, Reubi F C
Eur J Clin Pharmacol. 1980;17(3):165-71. doi: 10.1007/BF00561895.
The mode and site of action of the new diuretic agent piretanide were investigated in man. The effect of a single oral dose of 12 mg was compared with that of furosemide 80 mg p.o. iin 6 patients with the nephrotic syndrome. Piretanide showed a greater diuretic and natriuretic response than furosemide during maximal water diuresis, but the effect was similar in the hydropenic state. Like furosemide, piretanide decreased free water clearance relative to delivery during water diuresis and the reabsorption of solute-free water during hydropenia. This inhibitory action on both the concentrating and diluting urinary mechanisms demonstrates an effect of piretanide localized in the ascending limb of Henle's loop. Consistent alterations in glomerulur filtration rate, renal blood flow or filtration fraction were not observed.
对新型利尿剂吡咯他尼在人体中的作用方式和作用部位进行了研究。在6例肾病综合征患者中,比较了单次口服12mg吡咯他尼与80mg口服呋塞米的效果。在最大水利尿期间,吡咯他尼比呋塞米显示出更大的利尿和利钠反应,但在缺水状态下效果相似。与呋塞米一样,吡咯他尼在水利尿期间相对于输送量降低了自由水清除率,在缺水期间降低了无溶质水的重吸收。这种对尿液浓缩和稀释机制的抑制作用表明吡咯他尼的作用部位在髓袢升支。未观察到肾小球滤过率、肾血流量或滤过分数的持续变化。